Sell Sprint!: Again...
Health Care: Drugs
Amgen Inc (AMGN: NASDAQ)
$69.17 0.05 | 0.07%
02/07/12 - 04:00 PM ET
6.87M / 8.69M
Vol / Avg. Vol:68.71 / 69.12
Open / Prev. Close:68.15 - 69.24
Today's Range:47.66 - 70.00
52 Wk Range:7.72%
Performance YTD:TheStreet Rating:
Portfolios with AMGN
- Portfolio NameUser Type
- Contributor10 Health Care Stocks to Watch
- ContributorMost-Searched Stocks for th...
- ContributorHighest-Yielding Drug Stocks
- ContributorStocks At New 52-Week Highs...
- Contributor9 Defensive Stocks to Play
- ContributorStocks Rising On Unusual Vo...
- UserMON7NOV11
- UserBo
- UserAshok Aggressive Large Cap ...
- ContributorRocket Stocks for the Week ...
Latest AMGN Headlines from TheStreet
- FDA Skeptical of Amgen Drug Ahead of Panel 02.06.12 | 09:02 am
- Amgen Reaches New 52-Week High (AMGN) 02.01.12 | 12:02 pm
- 10 Health Care Stocks to Watch 01.27.12 | 05:01 pm
- Stocks Finish Mixed After GDP Data Disappoints 01.27.12 | 04:01 pm
- Stock Futures Drop on GDP Report 01.27.12 | 08:01 am
- Stocks to Watch: P&G, Ford, Honeywell (Update 2) 01.27.12 | 08:01 am
- Amgen's CEO Discusses Q4 2011 Results - Earnings Call Transcript 01.26.12 | 10:01 pm
- JC Penney, Netflix, Micromet Are Big Movers 01.26.12 | 04:01 pm
- 7 Hot Stocks on Traders' Radars 01.26.12 | 02:01 pm
- Amgen Acquires Micromet for $1.16 Billion 01.26.12 | 08:01 am
Press Releases for AMGN
- Amgen To Acquire Micromet - PR Newswire 01.26.12 | 08:01 am
- Amgen To Present At The 30th Annual J.P. Morgan Global Healthcare Conference - PR Newswire 01.04.12 | 04:01 pm
- FDA To Review Potential New Use Of XGEVA® (Denosumab) At Oncologic Drugs Advisory Committee Meeting - PR Newswire 12.29.11 | 05:12 pm
- Amgen And Watson Announce Collaboration To Develop And Commercialize Oncology Biosimilars - PR Newswire 12.19.11 | 04:12 pm
- Amgen And Watson Announce Collaboration To Develop And Commercialize Oncology Biosimilars - PR Newswire 12.19.11 | 04:12 pm
- Kevin Sharer, Amgen Chairman And CEO, Announces Plan To Retire With Robert Bradway To Become CEO On May 23, 2012; Sharer Will Continue As Chairman Of The Board Until End Of 2012 - PR Newswire 12.15.11 | 04:12 pm
- Amgen Announces 2012 First Quarter Dividend - PR Newswire 12.15.11 | 04:12 pm
- Amgen Announces Final Results Of Its Tender Offer - PR Newswire 12.14.11 | 09:12 am
- Amgen Presents Final Results From The Largest Phase 3 Open-Label Study Assessing The Safety And Efficacy Of Nplate® (Romiplostim) - PR Newswire 12.13.11 | 04:12 pm
- Amgen To Present At The 22nd Annual Oppenheimer Healthcare Conference - PR Newswire 12.09.11 | 04:12 pm
Partner Headlines for AMGN
- What Is A Moat? - Seeking Alpha 02.01.12 | 08:02 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- Don't Overlook The Buyback Achievers ETF (PKW) - ETF News And Commentary - Zacks 01.30.12 | 10:01 am
- Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach - Seeking Alpha 01.30.12 | 09:01 am
- Big Biotech Fuels M&A Activity - Seeking Alpha 01.29.12 | 07:01 am
- Amgen Misses; 2012 Outlook Strong - Analyst Blog - Zacks 01.27.12 | 10:01 am
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- Why Amgen Is Overvalued At $70 A Share - Seeking Alpha 01.23.12 | 09:01 am
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
- Top Undervalued Buys And Sells From Mega Fund PrimeCap Of Odyssey Funds - Seeking Alpha 01.14.12 | 08:01 am
